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Abstract
The development of a preventative HIV-1 vaccine remains a global public health priority. This 
will likely require the elicitation of broadly neutralizing antibodies (bNAbs) able to block 
infection by diverse viral strains from across the world. Understanding the pathway to 
neutralization breadth in HIV-1 infected people will provide insights into how bNAb lineages 
arise, a process that probably involves a combination of host and viral factors. Here we focus on 
the role of viral characteristics and evolution in shaping bNAbs during HIV-1 infection, and 
describe how these findings may be translated into novel vaccine strategies.
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Broadly neutralizing antibody responses to HIV-1 infection
One of the greatest challenges in the HIV-1 vaccine field remains the design of immunogens 
able to elicit antibodies that can neutralize diverse HIV-1 strains. While almost all HIV-1 
infected people develop neutralizing antibodies (NAbs) during the first year of infection, 
these antibodies are generally strain-specific [1–3]. This is because they target the variable 
regions of the viral envelope (Env), which differ profoundly between viruses [4–7]. It is 
only after several years of infection that antibodies develop which can recognize conserved 
epitopes present on many circulating strains [8–13]. Although a large proportion of infected 
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people develop some degree of neutralization cross-reactivity [12, 14], about 15–30% of 
individuals develop very broadly neutralizing antibodies (bNAbs). These bNAbs, which are 
sometimes able to neutralize 80–90% of viruses, are the types of antibodies that an HIV-1 
vaccine will ideally need to elicit. However, despite over 20 years of research and many 
different immunogen designs, bNAbs have not yet been elicited through vaccination, even in 
the RV144 vaccine trial that showed modest efficacy [15, 16]. Understanding the host 
factors (reviewed in [17–21]) and viral factors that contribute to the development of bNAbs 
in natural infection may provide valuable insights for vaccine design. Here we will focus 
specifically on the role of HIV-1 viral properties and evolution in shaping the development 
of bNAbs during infection.
Isolation of broadly neutralizing antibodies from infected people
Since 2009, the number of broadly neutralizing monoclonal antibodies (bNmAbs) isolated 
has surged from a handful to more than a 100 [22, 23], largely due to the development of 
new technologies for human antibody isolation including antigen-specific sorting, B cell 
culture with micro-neutralization assays for screening of individual wells, and multiplex RT-
PCR for immunoglobulin genes from single cells (reviewed in [22, 24, 25]). Many of these 
bNmAbs exhibit extraordinary breadth and potency [26–30], and have enabled the 
identification of five targets on the viral Env. These include the CD4 binding site (CD4bs) 
of gp120, the membrane proximal external region (MPER) of gp41, the C-sheet of the 
V1/V2 sub-domain (including the glycan at position 160) and the V3/C3 site on gp120 
(including the glycans at residues 301 and 332) [reviewed in [22, 24]. More recently, the 
identification of a fifth site of vulnerability at the interface between gp120 and gp41 has 
highlighted the existence of additional epitopes [30–33]. The characterization of large 
numbers of bNAbs to each of these sites has provided insights into the many modes of 
recognition that may exist within overlapping regions, leading to their description as 
supersites rather than epitopes [34].
Many of the bNmAbs have unusual features such as a skewed germ-line usage, high levels 
of somatic hypermutation associated with extensive affinity maturation (particularly true of 
CD4bs bNmAbs), polyreactivity and long variable heavy chain third complementarity 
determining regions (CDR-H3) [27–29, 35–38]. The long CDR-H3 was recently shown to 
be formed during the initial immunoglobulin recombination event in the CAP256-VRC26 
bNmAb lineage, suggesting that elicitation of these bNAbs would require engagement of 
rare germline B cells [39], although substantial affinity maturation was nonetheless still 
required for the development of breadth [38]. Together these features suggest a complex 
pathway towards bNAbs, posing significant challenges for vaccine development.
High viral levels are associated with, but not sufficient for neutralization 
breadth
Several studies have shown that the development of bNAbs is significantly associated with 
duration of infection, high viral load, low CD4+ counts, and a higher frequency of T 
follicular helper (Tfh) cells in the periphery, presumably a surrogate for germinal center Tfh 
cells [9, 12, 13, 17, 19, 20, 40–42]. Additionally, early preservation of both Tfh cells and B 
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cell function are associated with the later development of breadth [20]. These factors are 
generally consistent with a requirement for high levels of antigenic stimulation of B cells, 
and the need for T cell help in driving the maturation of breadth over years of infection. 
However, although antigenic load is generally necessary for the development of breadth, 
many infected subjects in the CAPRISA acute infection cohort with high viral loads failed to 
develop bNAbs over 4 years of infection [12] (Figure 1). In contrast, the occasional 
development of bNAbs in individuals with low viral loads [43], and perhaps the fact that 
most HIV-2 infected subjects develop bNAbs regardless of their viral loads [44–46] 
suggests that high viral load is not the sole determinant of breadth, and that other factors 
must also play a role.
Do characteristics of the infecting virus determine whether breadth 
develops?
One possible explanation for why only some infected people develop breadth is that the 
virus that infects these people has intrinsic features better able to stimulate the precursors of 
bNAbs. However, identifying specific envelope signatures of acute viruses in individuals 
who later develop breadth is complicated by the overall sequence diversity among 
circulating viruses, and by the fact that in many studies, viruses were sequenced at the same 
point that neutralization breadth was measured, not at the point of infection. Nonetheless, 
some signatures associated with breadth have been identified. Rademeyer et al. showed in 
subtype C viruses that bNAbs were associated with contemporaneous viruses with shorter 
variable loops (V1–V4) [41]. However, in contrast, in a much larger study of multiple 
subtypes, Hraber et al. showed that bNAbs were associated with contemporaneous viruses 
with longer V1V2 regions [47]. In a computational comparison of multi-subtype sequences 
from subjects with breadth and those without, Gnanakaran et al. identified six signatures 
associated with breadth, mostly in the CD4/coreceptor-binding site of the viral envelope 
[48]. However all three of these studies were limited in that it is likely that the virus that was 
sequenced would already have escaped bNAbs, making it impossible to determine if these 
features are associated with elicitation of breadth or a consequence of breadth. In contrast, in 
a study of viruses sequenced prior to breadth, Van Kerkhof et al. showed that shorter V1 
loops, less overall glycosylation, and the absence of a specific glycan at 332 (which forms 
part of a major bNAb supersite, see above) were associated with increased breadth [49]. 
Further studies such as this in large diverse cohorts are needed to identify which virological 
features precede the development of breadth
While these examples are suggestive, overall it remains unclear how much of the 
development of breadth is determined by features of the infecting virus (Box 1). Because 
neutralization breadth normally emerges years after infection, the infecting virus may be of 
less relevance than the later viral variant that actually engages the naïve B cell encoding the 
bNAb precursor (the bNAb-initiating Env, Figure 2). These viral stimuli are often hard to 
define without detailed longitudinal studies that require the isolation of bNmAbs, followed 
by deep sequencing at multiple earlier time points to precisely define when the earliest 
mAb-related transcripts can be detected (Figure 2). To date only two such studies have been 
reported [38, 50], In the study of the CAP256-VRC26 lineage of bNmAbs, the earliest time 
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point at which related transcripts could be detected was 38 weeks after primary infection, 
and 23 weeks after superinfection. By this time, the superinfecting virus was no longer 
present, having been replaced by viral recombinants/variants, one of which presumably 
better reflects the bNAb-initiating Env [38].
Box 1
Outstanding questions
• Are envelopes from subjects with breadth intrinsically better immunogens?
• Does superinfection and increased diversity simply ‘stack the odds’ in favour of 
encountering an Env able to bind and trigger the appropriate B cell, or is there a 
more mechanistic explanation for how diversification drives breadth?
• Can the immune system be ‘coaxed’ along the pathway to breadth through 
exposure to serial immunogens?
Identification of the precise Env sequence of the virus that stimulated bNAb lineages 
through such longitudinal studies may be extremely useful for immunogen design. A notable 
feature of the unmutated common ancestors (UCA), or germline reverted approximations of 
many bNAbs, is their general lack of binding to HIV-1 Env [51–54]. While much of this is 
likely due to the paucity of information used to infer these UCAs, recent studies have 
defined barriers preventing the binding of UCAs to viral Env. For example, germline-
reverted versions of CD4bs bNmAbs such as VRC01, NIH45–46, 3BNC60, and 12A21, all 
of which use the VH1-2 antibody alleles, generally do not bind viral Env because of 
obstruction of the light chain [55]. Deletion of a highly conserved glycan at residue 276 in 
Env results in binding of both heavy and light chains and activation of B cells expressing 
germline VH1-2 receptors. This finding may account for the inability of previous 
immunogens to elicit CD4bs antibodies, and as N276-lacking natural Env are rare (5% of 
HIV-1 strains) may also explain why such specificities are not often elicited in natural 
infection. Overall, studies that identify bNAb-initiating viral Env (either naturally-occurring 
or engineered to become germ-line reactive) are important to identify for translation into 
immunogenicity studies [51–55].
Does early viral diversity drive the development of bNAbs?
Another potential contributor to breadth is viral diversity. One of the first observations that 
suggested that the quasispecies diversity (rather than the founder virus that initiated 
infection, or the overall viral loads) may contribute to breadth came from the findings that 
early viral diversity was associated with the subsequent development of bNAbs [40]. The 
possibility that exposure to diverse envelopes may contribute to breadth suggested that 
individuals who are superinfected with HIV-1, and thus exposed to multiple variants/
recombinants, should also develop better bNAbs, and indeed two studies of superinfection 
support this. Powell et al. showed that dual infection resulted in enhanced breadth, though in 
this study confounding factors such as the duration of infection could not be excluded [56]. 
A more recent study reported both increased breadth and potency in superinfected 
individuals compared with singly infected subjects, with breadth emerging within a year of 
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superinfection, independently of viral load and CD4+ T cell counts [57]. Intriguingly, in this 
study, both intersubtype superinfection and the persistence of both infecting viruses was 
linked to increased breadth, again suggesting that exposing the immune system to diverse 
viruses enhances breadth. Furthermore, the developmental pathway for bNAbs in CAP256, 
who was superinfected, was recently reported [38]. However, it is important to note that in 
this case, the role of superinfection, beyond simply providing an additional mechanism for 
viral diversification through recombination, is unclear. If superinfection does indeed drive 
enhanced breadth, one unanswered question is whether superinfection and increased 
diversity is simply additive and ‘stacks the odds’ in favor of encountering an Env able to 
bind and trigger the appropriate B cell, or whether the presence of multiple genotypes 
exponentially drives B cell affinity maturation, suggesting a more mechanistic explanation 
for these findings (Box 1).
Viral diversification during the development of bNAbs: chicken or egg?
In addition to the association of viral diversity prior to bNAbs, recent studies have also 
shown profound viral diversification as bNAbs emerge. Viral neutralization escape is well 
described, with substitutions, glycan shifts, and indels frequently associated with the 
development of strain-specific NAbs [2, 58, 59]. Despite the conserved nature of the bNAb 
epitopes, it has become clear that HIV-1 is also able to escape from bNAbs very effectively 
[42, 60–64], consistent with the fact that the development of such antibodies has not been 
shown to confer an obvious clinical benefit [12, 13]. This suggests that, as with strain-
specific NAbs, the development of bNAbs would drive increased viral diversification as 
viral escape occurs. Indeed, Euler et al. reported that the peak in envelope sequence 
diversity coincided with the peak of bNAb titers [65]. However, the two recent studies of the 
ontogeny of bNmAbs, namely the CH103 CD4bs lineage [50] and the CAP256-VRC26 V2-
glycan lineage [38] suggested that in addition to bNAbs driving viral escape, the opposite 
may also be true, i.e., viral diversification within epitopes through escape may contribute to 
the maturation of bNAbs. These, and other studies have provided important clues as to the 
precise mechanisms whereby viral evolution may drive increased breadth; namely, through 
the creation or exposure of bNAb epitopes, or through the generation of multiple 
immunotypes (or epitope variants), described in more detail below.
Immune escape from strain-specific antibodies and the creation of bNAb 
epitopes
One of the more common bNAb specificities detected in cohorts of infected individuals are 
those that target the V3/C3 supersite that includes the glycan at position 332 (PNG332) on 
the viral Env [27, 66, 67]. A longitudinal study of two subjects shown to develop PNG332-
dependent bNAbs surprisingly showed that in both cases the infecting virus did not have a 
glycan at that position (Figure 3A) [42]. Single genome sequencing of viral RNA from 
longitudinal samples showed the evolution of the 332 glycan and the V3/C3 bNAb epitope 
by 6 months of infection, prior to bNAb development. Plasma mapping studies showed the 
presence of strain-specific NAb responses to the V3/C3 region of the envelope [42], and 
further showed that the insertion of the 332 glycan mediated escape from this early strain-
specific antibody. Thus neutralization escape from strain-specific NAbs resulted in viral 
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convergence towards a conserved glycan motif (the 332 glycan is present on 72% of global 
viruses, see pie chart, Figure 3A) creating the epitope targeted by later bNAbs [68]. This 
pattern of selection of the 332 glycan was evident at a population level using more than 
7,300 single genome derived envelope sequences from 68 acute and 62 chronic HIV-1 
infections [42]. However, although the absence of this glycan on infecting viruses has been 
associated with the subsequent development of bNAbs in a separate study (see above and 
[49]), this pattern of evolution does not always result in the development of bNAbs, again 
highlighting the role of other factors in driving this process.
The role of strain-specific NAbs in forming bNAb epitopes was similarly shown in a 
separate study of CAP257, an infected subject who developed V2-directed bNAbs [64]. 
Here, an initial strain-specific NAb response was directed to an N167 residue in V2. N167 is 
very rare among global isolates, occurring in only 5.6% of sequences (pie chart, Figure 3B). 
Viral escape from this initial response resulted in a N167D mutation by 30 weeks (i.e., a 
mutation towards the consensus, with D167 present in 87% of global viruses). Viral escape 
therefore here again resulted in the creation of a V2 epitope that was much more 
representative of global viruses and presumably became the stimulus for the V2 bNAb 
response.
While in both these studies, escape from a strain-specific response created a conserved 
epitope that became the target of later bNAbs [42, 64], a key unanswered question is 
whether (i) the strain-specific C3- or V2-directed NAbs were part of the same lineage as the 
bNAbs, and matured to target the emerging 332 glycan/D167 residue, or (ii) whether the 
creation of the bNAb epitope was driven by an unrelated antibody lineage to an overlapping 
epitope. Although the former scenario may be more amenable to immunogen design, the 
latter has been directly demonstrated in a follow-up study of the CD4bs bNmAbs described 
above [69]. In addition to the CH103 bNAb lineage, a second NAb lineage, the CH235 
clonal lineage, was isolated from the same donor, CH505. CH235 NAbs drove viral escape 
through several mutations in the D loop of the viral envelope, which forms part of the 
CD4bs bNAb epitope. These mutations, while effectively mediating escape from CH235-
related antibodies, surprisingly resulted in viral variants becoming more sensitive to the 
developing CH103 bNAb lineage, thereby contributing to the maturation of breadth [69]. 
This study, through the use of isolated mAbs and viral mutants conclusively demonstrated 
the role of viral escape from strain-specific NAbs in the creation of bNAb lineages, and led 
to the concept of co-operation between different antibody lineages in the development of 
neutralization breadth.
Viral escape and exposure of occluded bNAb epitopes
In CAP257, the same subject who developed bNAbs to the V2 region (described above), a 
second bNAb response developed later in infection, this time targeting the CD4bs [64]. This 
enabled us to characterize the relationship between these two evolving specificities [64]. 
Viral escape from the V2-directed bNAbs drove the deletion of a highly conserved glycan at 
position 160 in V2 [64]. This deletion resulted in unusual exposure of the CD4bs, which 
subsequently became the target for the next wave of bNAbs. Thus, viral escape may force 
the exposure of otherwise occluded conserved epitopes, facilitating the development of 
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breadth. Intriguingly, V2 and CD4bs antibodies were found in three of the four individuals 
where multiple bNAbs have been described, suggesting this may be a common 
developmental pathway for consecutive specificities that might be useful for immunogen 
design [64, 70–72]. These data suggest the possibility that escape from bNAbs, at the 
expense of potentially deleterious exposure of occluded epitopes, is the result of a trade-off 
between the need for escape at sites that are normally conserved, and fitness in the presence 
of bNAbs.
Viral escape from bNAbs creates novel immunotypes that drive breadth
Several studies have suggested that bNAbs may mature from earlier binding or strain-
specific neutralizing antibodies [38, 50, 64, 73]. This need for ongoing antibody maturation 
suggests incomplete viral escape from bNAb precursors, which would otherwise not 
continue to evolve. This is supported by a comparison of the CH103 and CH235 mAbs, 
which showed that the extent and rate of viral escape from the two lineages differed. 
Complete escape from the CH235 mAb lineage occurred by 53 weeks of infection (though it 
is not known exactly when the lineage was initiated). In contrast, members of the more 
broadly neutralizing CH103 lineage continued to neutralize viral variants as far as 100 
weeks post-infection, which is at least 86 weeks after the antibody lineage was first detected 
by deep sequencing. These findings suggest that the continued ability to neutralize 
autologous viral variants might be an important aspect of bNAb maturation [69]. There is 
evidence to support this notion for both strain-specific nAbs and bNAbs. Studies of strain-
specific plasma responses to autologous viruses have shown differential sensitivity of viral 
variants at a given time point to strain-specific NAbs [69, 74]. Similarly, Murphy et al. 
showed that two antibody light chain variants paired with a single heavy chain displayed 
differential neutralization of autologous viruses containing escape mutations at the base of 
V3/C3 region [75]. These findings suggested that viral evolution drives strain-specific NAbs 
to recognize amino acid variants within a given epitope [75]. The subject of this study did 
not go on to develop bNAbs, however Wibmer et al. documented similar findings in 
CAP257 who did develop bNAbs to the CD4bs [64]. This study combined detailed mapping 
of evolving plasma specificities with longitudinal analyses of viral escape mutations, to 
show that the CD4bs bNAbs acquired increased breadth in response to the serial emergence 
of escape mutations within the epitope [64]. The early CD4bs bNAb response in CAP257 
was only able to neutralize heterologous viruses with an N279 residue in the D loop, part of 
the bNAb epitope. Global viruses generally contain either a N279 (50%) or a D279 (47%). 
Thus an antibody with complete dependence on N279 would only be able to neutralize half 
of global viruses, whereas the ability of a bNAb to tolerate either a N279 or a D279 would 
theoretically confer double the potential neutralization breadth. Interestingly, early escape 
from the initial CD4bs response was mediated by a N279D mutation. The maturation of the 
plasma response to tolerate this escape mutation in circulating viral variants corresponded 
with the increased breadth of this plasma, and with the ability to neutralize heterologous 
viruses with either an N or D at this position. The similar maturation of this CD4bs bNAb 
response to neutralize later autologous escape variants containing mutations at additional 
sites within the epitope (at residues 276 and 456) prior to complete neutralization escape 
only 70 weeks later supports a model where escape mutants result in evolution of the bnAb 
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response to tolerate variation at some sites within an epitope, with a ‘footprint’ becoming 
increasingly focused on core conserved motifs (Figure 4). Thus the evolving antibody 
swarm in an infected individual may be driven towards breadth through exposure to multiple 
epitope variants generated as the viruses ‘toggles’ between early escape pathways, before 
complete viral escape. This ability to recognize multiple immunotypes, emerging as a result 
of neutralization escape has also been associated with increased breadth in other studies [38, 
61, 76]. These data suggest this may be a common feature of subjects with breadth, with the 
potential to be exploited for immunogen design.
Concluding remarks: implications for HIV vaccine design
Studies of the viral drivers of breadth are based on the premise that, unlike host factors, 
defining the virological factors associated with breadth may provide opportunities for 
translation into immunogen design. One unanswered question is whether viruses infecting 
people who later develop bNAbs are intrinsically better immunogens. This possibility is 
supported by the observation that BG505, an Env that forms unusually stable trimers, and as 
such is a major current focus for immunogen design, was derived from an HIV-1-infected 
infant who developed bNAbs. Whether this trimeric recombinant Env protein is able to 
induce bNAbs in vaccinated individuals remains to be determined [77–79]. Regardless, it is 
unlikely to be this simple, and the unusual features of the bNmAbs together with the fact 
that a minority of individuals develop very broad responses, suggest that the development of 
breadth is a complex interaction of multiple factors. However the data described here 
suggest the evolving virological features are likely to play a key role. Comparison of bNAb 
Env with those from subjects who fail to develop significant breadth is likely to continue to 
provide insights into viral signatures of breadth. However immunogenicity studies would be 
the ‘gold standard’ in testing these signatures to define whether their incorporation into 
vaccine strategies may be valuable.
The increasing appreciation that viral evolution may be important in shaping bnAbs 
(through at least three mechanisms, summarized in Figure 5) has provided support for the 
notion that exposure of the immune system to epitope variants through vaccination may 
drive the development of enhanced breadth [22, 23, 25, 38, 42, 50, 64, 69, 80–82]. Thus, a 
vaccine strategy may need to begin with a (natural or engineered) Env immunogen able to 
engage the appropriate B cell precursor, followed by the sequential use of immunogens 
incorporating key epitope variants associated with driving breadth. Indeed, such studies, 
using sequentially isolated envelopes from infected subjects who rapidly developed breadth 
have shown moderate improvements in NAb responses [80, 81, 83]. Emerging data that 
better defines key immunotypes and synergies between specificities (such as that between 
the V2 and CD4bs bNAb epitopes) will provide exciting new opportunities for testing these 
concepts in immunization strategies.
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• Many HIV infected people develop broadly neutralizing antibodies (bNAbs).
• Viral evolution shapes the maturation of bNAbs through creation and exposure 
of epitopes.
• Epitope variants, or ‘immunotypes’, drive increased breadth.
• Incorporating viral evolution into vaccines may be necessary to elicit bNAbs.
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Viral load is necessary but not sufficient for neutralization breadth. Infected subjects from 
the CAPRISA acute infection cohort stratified by viral load and neutralization breadth 
(defined as neutralizing >40% of a panel of 42 heterologous viruses at three years post-
infection [12]). Subjects with bNAbs and high viral load are shown in red, no bNAbs despite 
high viral load in green, and those with no bNAb and low viral load in blue. X-axis, weeks 
post-infection, Y-axis, viral load (RNA copies/ml).
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Longitudinal bNAb and virus co-evolution studies will enable the identification of viral 
envelopes that engaged the B cell expressing the unmutated common ancestor (UCA) of a 
bNAb lineage (the bNAb-initiating Env). (A) bNmAb isolation from infected subjects 
followed by retrospective deep sequencing at multiple time points to identify the time point 
at which the unmutated common ancestor emerged. (B) Parallel virological studies, also at 
multiple time points, will enable the identification of the bNAb-initiating Env.
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Strain-specific antibodies result in the creation of bNAb epitopes through viral escape. (A) 
Strain-specific antibodies to the C3 region result in viral escape through the addition of a 
glycan at position 332 [42]. This glycan, conserved in 72% of global viruses (pie chart, 
right) became the target of maturing/newly developing NAbs, resulting in the development 
of bNAbs. (B) Similarly, a strain-specific V2 response targets the rare N167 residue (present 
in only 5.6% of global viruses). Viral escape occurs through a N167D mutation, with D167 
representing the consensus at the position, present in 87% of viruses (pie chart, right), 
resulting in the development of bNAbs.
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Model for the maturation of strain-specific plasma responses to acquire breadth through 
exposure to developing immunotypes (epitope variants). (A) Strain-specific antibodies 
(black) recognize defined epitopes (shown in gray, in a 4-domain lock-and-key schematic). 
(B) Early NAbs drive initial viral escape mutations (represented as a yellow shape at the 
fourth domain) within epitopes. Affinity maturation enables the maturing NAbs to tolerate 
both the gray and the yellow variants, through a more focused footprint. (C) Further viral 
escape occurs (orange shape, first domain), resulting in maturation of NAbs to tolerate 
epitope variation at domains 1 and 4. (D) The emergence of further (red) mutations at 
domain 1, 3, and 4 results in maturation of NAbs to focus on a conserved epitope core (or 
‘footprint’, shaded in the gray box) present on heterologous viruses, enabling the maturation 
of bNAbs. Note: an earlier iteration of this model was published in [17].
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Summary of mechanisms whereby viral evolution shapes the development of HIV-1 
neutralizing breadth. This can occur through (A) creation of bNAb epitopes through viral 
escape from strain-specific antibodies, (B) exposure of bNAb epitopes through viral escape 
mutations, and (C) affinity maturation of NAb lineages by exposure to different 
immunotypes.
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